


IN THE CLAIMS

1. (Currently Amended): ~~An active substance combination, characterized in that it comprises~~

A composition comprising components (A) and (B) where:

(A) is at least one compound with neuropeptide Y (NPY)-receptor affinity[[,]]

selected from the group consisting of compounds of general formula (Ia),



(Ia)

wherein

R^{1a}, R^{2a}, R^{3a}, R^{4a} are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic

ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ~~ring-system~~ ring-system, a nitro, cyano, —OR^{12a} , —OC(=O)R^{13a} , —SR^{14a} , —SOR^{14a} , $\text{—SO}_2\text{R}^{14a}$, $\text{—NH—SO}_2\text{R}^{14a}$, $\text{—SO}_2\text{NH}_2$ and $\text{—NR}^{15a}\text{R}^{16a}$ moiety,

R^{5a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical,

R^{6a} , R^{7a} , R^{8a} , R^{9a} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano and a COOR^{17a} moiety,

A^a represents a bridge member $\text{—CHR}^{18a}\text{—}$ or $\text{—CHR}^{18a}\text{—CH}_2\text{—}$,

R^{10a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{11a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group

and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, or an optionally at least mono substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, or

R^{10a} and R^{11a} together with the bridging nitrogen atom form an optionally at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring that may contain at least one further heteroatom as a ring member and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem,

R^{12a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{13a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group

and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{14a} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{15a} and R^{16a} each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

or R^{15a} and R^{16a} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member,


R^{17a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing

cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{18a} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, ~~or a solvate~~, respectively, and

(B) is at least one compound with 5-HT₆ receptor affinity selected from the group consisting of the benzoxazinone-derived sulfonamide compounds of general formula (Ib), (Ic), (Id), (Ie), (If), (Ig), and (Ih);

wherein general formula (Ib) is:



(Ib)

wherein

R^{1b} , R^{2b} , R^{3b} , R^{4b} are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro, cyano, $-OR^{10b}$, $-O(C=O)R^{11b}$, $-(C=O)OR^{11b}$, $-SR^{12b}$, $-SOR^{12b}$, $-SO_2R^{12b}$, $-NH-SO_2R^{12b}$, $-SO_2NH_2$ and a $-NR^{13b}R^{14b}$ moiety,

R^{5b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical,

R^{6b} , R^{7b} , R^{8b} , R^{9b} are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano group and a $COOR^{15b}$ moiety,

W^b represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

an optionally at least mono-substituted aryl or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene or alkenylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

a $NR^{16b}R^{17b}$ -moiety, or

a COR^{18b} -moiety,

R^{10b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono-

or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{11b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{12b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{13b} and R^{14b} each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded

via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

or R^{13b} and R^{14b} together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member,


R^{15b} represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

R^{16b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

R^{17b} represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, and

R^{18} represents an optionally at least mono-substituted aryl radical optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, ~~or a solvate~~, respectively[[,]];

~~and, compounds derived from sulfonamide of~~
general formula (Ic) is:[[,]]



(Ic)

wherein

R^{1c} represents hydrogen, an optionally at least mono-substituted, linear or branched alkyl radical, an optionally at least mono-substituted phenyl radical or an optionally at least mono-substituted benzyl radical,

R^{2c} represents a $-NR^{4c}R^{5c}$ moiety or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing mono- or bicyclic cycloaliphatic ringsystem,

R^{3c} represents hydrogen or an optionally at least mono-substituted, linear or branched alkyl radical,

R^{4c} and R^{5c} , identical or different, represent hydrogen or an optionally at least mono-substituted, linear or branched alkyl radical, or

R^{4c} and R^{5c} together with the bridging nitrogen atom form an optionally at least mono-substituted, saturated or unsaturated heterocyclic ring, which may contain at least one

further heteroatom as a ring member and/or may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing mono- or bicyclic cycloaliphatic ringsystem,


A^c represents an optionally at least mono-substituted mono- or polycyclic aromatic ringsystem, which may be bonded via an optionally at least mono-substituted alkylene-, an optionally at least mono-substituted alkenylene- or an optionally at least mono-substituted alkynylene group and/or may contain at least one heteroatom as a ring member in one or more of its rings,

nc represents 0, 1, 2, 3 or 4;

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a corresponding physiologically acceptable salt ~~or a corresponding solvate;~~

~~and compounds of the~~

general formula (Id) is:



(Id)

R^{1d} represents a —NR^{8d}R^{9d} radical or a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, which may contain at least one heteroatom as a ring

member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

R^{2d} , R^{3d} , R^{5d} , R^{6d} and R^{7d} , identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl or heteroaryl radical,

R^{4d} is hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

R^{8d} and R^{9d} , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or R^{8d} and R^{9d} together with bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one additional heteroatom as a ring member and/or may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one heteroatom as a ring member,


A^d represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings, and

n_d is 0, 1, 2, 3 or 4;

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, ~~or a corresponding solvate thereof,~~

and ~~sulphonamide-derived compounds of~~

general formula (Ie) is: [[,]]



wherein

R^{1e} represents a $—NR^{8e}R^{9e}$ radical or a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, which may optionally contain at least one heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one heteroatom as a ring member,

R^{2e} , R^{3e} , R^{4e} , R^{6e} and, R^{7e} , identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical or an optionally at least mono-substituted phenyl or an optionally at least mono-substituted heteroaryl radical,

R^{5e} represents hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

R^{8e} and R^{9e} , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or R^{8e} and R^{9e} together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one


additional heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, mono- or bicyclic cycloaliphatic ring system which may optionally contain at least one heteroatom as a ring member,

A^e represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings and

ne is 0, 1, 2, 3 or 4;

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, at any mixture ratio, or a corresponding, physiologically acceptable salt, ~~or a corresponding solvate; and sulphonamide-derived compounds of~~

general formula (If) is: [[,]]



(If)

wherein

R^{1f} represents a $-NR^{8f}FR^{9f}$ radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at

least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

R^{2f} , R^{3f} , R^{4f} , R^{5f} and R^{7f} , identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl or optionally at least mono-substituted heteroaryl radical,

R^{6f} represents hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,


R^{8f} and R^{9f} , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or R^{8f} and R^{9f} , together with the bridging nitrogen atom, form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one further heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

A^f represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings, and

nf is 0, 1, 2, 3 or 4;

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, at any mixture ratio, or a corresponding, physiologically acceptable salt; ~~or a corresponding solvate and sulphonamide-derived compounds of~~

general formula (Ig) is:



(Ig)

wherein

R^{1g} is a $—NR^{8g}R^{9g}$ radical or a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, which may optionally contain at least one heteroatom as a ring member and which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system which may optionally contain at least one heteroatom as a ring member,

R^{2g} , R^{3g} , R^{4g} , R^{5g} and R^{6g} , identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl radical or an optionally at least mono-substituted heteroaryl radical,

R^{7g} represents hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

R^{8g} and R^{9g} , identical or different, represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or

R^{8g} and R^{9g} together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one additional heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one heteroatom as a ring member,


A^g represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings, and

ng is 0, 1, 2, 3 or 4;

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, at any mixture ratio, or a corresponding, physiologically acceptable salt, ~~or a corresponding solvate,~~; and

~~and sulphonamide derived compounds of~~

general formula (Ih) is:



wherein

R^{1h} represents a $—NR^{7h}R^{8h}$ radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

R^{2h} , R^{3h} , R^{4h} , R^{5h} and R^{6h} , identical or different, each represent hydrogen, halogen, cyano, nitro, a saturated or unsaturated, linear or branched aliphatic radical, a linear or branched alkoxy radical, a linear or branched alkylthio radical, hydroxy, trifluoromethyl, a saturated or unsaturated cycloaliphatic radical, an alkylcarbonyl radical, a phenylcarbonyl or a $—NR^{9h}R^{10h}$ group,

R^{7h} and R^{8h} , identical or different, each represent hydrogen or a saturated or unsaturated, optionally at least mono-substituted linear or branched aliphatic radical, or R^{7h} and R^{8h} , together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

R^{9h} and R^{10h} , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or R^{9h} and R^{10h} , together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

A^h and B^h, identical or different, each represent a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical or A^h and B^h, together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic, optionally at least mono-substituted cycloalkyl ring, and

nh is 0, 1, 2,3, or 4,

optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding physiologically acceptable salt thereof ~~or a corresponding solvate thereof~~.

2. (Currently Amended): ~~The combination~~ composition according to claim 1, which ~~characterized in that it~~ comprises 1-99% by weight of component (A) and 99-1% by weight of component (B), more preferably 10-80% by weight of component (A) and 90-20% by weight of component (B), referring those percentages to the total weight of both components (A) and (B).

3. (Currently Amended): ~~A medicament comprising an active substance combination according to any one of the claims 1 or 2 and optionally~~

The composition of claim 1, further comprising one or more pharmacologically acceptable adjuvants.

4. (Currently Amended): The composition of claim 3 in an amount sufficient

~~A medicament according to claim 3,~~ for regulation of appetite, for maintenance, increase or reduction of body weight, for prophylaxis and/or treatment of disorders related to food ingestion, ~~preferably for~~ prophylaxis and/or treatment of obesity, anorexia, cachexia,

bulimia, diabetes, ~~preferably~~ type II diabetes (non-insulin-dependent diabetes mellitus), ~~or for~~
prophylaxis and/or treatment of a gastrointestinal tract disorders, preferably of the irritable
bowel syndrome, ~~for~~ prophylaxis and/or treatment of a peripheral nervous system disorder
~~Peripheral Nervous System Disorders, or a central nervous system disorder Central Nervous~~
~~System Disorders~~, arthritis, epilepsy, anxiety, panic, depression, cognitive disorders, memory
disorders, cardiovascular diseases, senile dementia processes, ~~such as~~ Alzheimer's,
Parkinson's and/or Huntington's Disease, schizophrenia, psychosis, infantile hyperkinesia
(ADHD, attention deficit/hyperactivity disorder), pain, hypertensive syndrome,
inflammatory diseases, immunologic diseases or for improvement of cognition.

5. (Currently Amended): A method for treating a subject comprising administering
an effective amount of the composition of claim 1, wherein said subject is in need of
treatment for regulation of appetite, for maintenance, increase or reduction of body weight;
for a disorder related to food ingestion; for obesity, anorexia, cachexia, bulimia, diabetes,
type II diabetes (non-insulin-dependent diabetes mellitus), a gastrointestinal tract disorder,
irritable bowel syndrome, a peripheral nervous system disorder, a central nervous system
disorder, arthritis, epilepsy, anxiety, panic, depression, a cognitive disorder, a memory
disorder, or for improvement of cognition; for a cardiovascular disease, senile dementia,
Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, psychosis,
infantile hyperkinesia (ADHD, attention deficit/hyperactivity disorder), pain, hypertensive
syndrome, an inflammatory disease; or for an immunologic disease

~~Use of the combination according to any one of claims 1 or 2, for manufacture of a~~
~~medicament for regulation of appetite.~~

6.-29. (Cancelled)

30. (Currently Amended): ~~A pharmaceutical formulation, characterized in that it comprises an active substance combination according to any one of claims 1 or 2 and optionally~~

A pharmaceutical composition comprising the composition of claim 1 and one or more pharmacologically acceptable adjuvants.

31. (Currently Amended): The pharmaceutical formulation according to claim 30, ~~characterized in that it~~ which is present in solid pharmaceutical forms such as tablets, tablets, chewing tablets, chewing gums, dragées, capsules, suppositories, powder preparations, transdermal therapeutic systems, transmucosal therapeutic systems, or in liquid and semi-liquid pharmaceutical forms such as drops or such as juice, sirup, solution, emulsion, suspension, preferably in form of tablets, capsules, drops or solution.

32. (Currently Amended): The pharmaceutical ~~formulation~~ composition according to claim 30, ~~characterized in that it~~ which is present in form of multiple particles, preferably microtablets, microcapsules, microspheroids, granules, crystals or pellets, optionally compacted in a tablet, filled in a capsule or suspended in a suitable liquid.

33. (Currently Amended): The pharmaceutical formulation according to claim 30 ~~one or more of claims 30-32, characterized in that it is~~ in a form suitable for oral, intravenous, intramuscular, subcutaneous, intrathecal, epidural, buccal, sublingual, pulmonal, rectal, transdermal, nasal or intracerebroventricular application, ~~preferably oral or intravenous.~~

34. (Currently Amended): The pharmaceutical composition of claim 30, wherein ~~formulation according to one or more of claims 30-33, characterized in that~~ at least one of the components of the active substance combination (A) or (B) is present at least partially in sustained-release form.

35. (Currently Amended): The pharmaceutical ~~formulation~~ composition according to claim 34, ~~characterized in that the medicament~~ which has at least one coating or one matrix comprising at least one material, which sustains active substance release.

36. (Currently Amended): The pharmaceutical ~~formulation~~ composition according to claim 35, ~~characterized in that the~~ comprising a sustained-release material that is based on an optionally modified, water-insoluble, natural, semisynthetic or synthetic polymer, ~~or a natural wax or fat or fatty alcohol or semisynthetic or synthetic fatty acid, or on a mixture of at least two of these~~ sustained release materials ~~aforementioned components~~.

37. (Currently Amended): The pharmaceutical ~~formulation~~ composition according to claim 36, ~~characterized in that the~~ comprising a water-insoluble polymer is based on an acrylic resin, ~~which is preferably~~ selected from the group of poly(meth)acrylates, poly(C₁₋₄)dialkylamino(C₁₋₄)alkyl (meth)acrylates and/or copolymers thereof or a mixture of at least two of the afore-mentioned polymers.

38. (Currently Amended): The pharmaceutical ~~formulation~~ composition according to claim 36, ~~characterized in that the~~ comprising at least one water-insoluble polymer[[s]] that is ~~a~~ are cellulose derivative[[s]], ~~preferably~~ alkyl cellulose, ~~and even more preferably~~ ethyl cellulose, or a cellulose ester[[s]].

39. (Currently Amended): The pharmaceutical formulation according to claim 36, ~~characterized in that the wax is~~ comprising at least one of carnauba wax, beeswax, glycerol monostearate, glycerol monobehenate, glycerol ditripalmitostearate, microcrystalline wax or a mixture of at least two of these components.

40. (Currently Amended): The pharmaceutical formulation according to claim 36, ~~wherein said polymers have been combined with one or more of claims 36 to 39,~~ ~~characterized in that polymers have been used in combination with~~ one or more plasticizers.

41. (Currently Amended): The pharmaceutical composition of claim 30, wherein in ~~addition to said formulation according to one or more of claims 30 to 40, characterized in that~~ ~~besides the~~ sustained-release form, at least one of the active substance components (A) or (B) is present in a non-sustained-release form.

42. (New): The composition of claim 1, wherein (B) is a compound of general formula (1b).

43. (New): The composition of claim 1, wherein (B) is a compound of general formula (1c).

44. (New): The composition of claim 1, wherein (B) is a compound of general formula (1d).

45. (New): The composition of claim 1, wherein (B) is a compound of general formula (1e).

46. (New): The composition of claim 1, wherein (B) is a compound of general formula (1f).

47. (New): The composition of claim 1, wherein (B) is a compound of general formula (1g).

48. (New): The composition of claim 1, wherein (B) is a compound of general formula (1h).

49. (New): The composition of claim 1, wherein said compound with neuropeptide Y (NPY) receptor affinity is 2-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidyn-1-yl]-N-(9-oxo-9H-fluoren-3-yl)acetamide hydrochloride.

50. (New): The composition of claim 1, wherein said compound with 5-HT₆ receptor affinity is N-3-(2-dimethylaminoethyl)-1H-indol-5-yl]-5-chloronaphthalene-2-sulphonamide.

51. (New): The composition of claim 1 wherein

(A) is 2-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidyn-1-yl]-N-(9-oxo-9H-fluoren-3-yl)acetamide hydrochloride and

(B) is N-3-(2-dimethylaminoethyl)-1H-indol-5-yl]-5-chloronaphthalene-2-sulphonamide.

52. (New): A method for regulating appetite comprising administering an effective amount of the composition of claim 1 to a subject in need thereof.

53. (New): The method of claim 52, wherein in said composition

(A) is 2-[4-(8-methyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidin-1-yl]-N-(9-oxo-9H-fluoren-3-yl)acetamide hydrochloride and

(B) is N-3-(2-dimethylaminoethyl)-1H-indol-5-yl]-5-chloronaphthalene-2-sulphonamide.

54. (New): A method for maintenance of body weight, for increasing body weight, for treatment of anorexia, or for treatment of cachexia comprising administering an effective amount of the composition of claim 1 to a subject in need thereof.

55. (New): A method for reduction of body weight, for treatment of obesity, or for treatment of bulimia comprising administering an effective amount of the composition of claim 1 to a subject in need thereof.

56. (New): A method for treating a disorder related to food ingestion comprising administering an effective amount of the composition of claim 1 to a subject in need thereof.

57. (New): A method for treating cardiovascular disease comprising administering an effective amount of the composition of claim 1 to a subject in need thereof.

58. (New): A method for treating diabetes or type II diabetes (non-insulin-dependent diabetes mellitus) comprising administering an effective amount of the composition of claim 1 to a subject in need thereof.

59. (New): A method for treating a gastrointestinal tract disorder or irritable bowel syndrome comprising administering an effective amount of the composition of claim 1 to a subject in need thereof.

60. (New): A method for treating a peripheral nervous system disorder or a central nervous system disorder comprising administering an effective amount of the composition of claim 1 to a subject in need thereof.

61. (New): A method for treating epilepsy, anxiety, panic, depression, a cognitive disorder, senile dementia, schizophrenia, psychosis, infantile hyperkinesia (ADHD, attention deficit/hyperactivity disorder), pain, hypertensive syndrome, Alzheimer's disease, Parkinson's disease, or Huntington's disease comprising administering an effective amount of the composition of claim 1 to a subject in need thereof.

62. (New): A method for treating a memory disorder or for improving cognition comprising administering an effective amount of the composition of claim 1 to a subject in need thereof.

63. (New): A method for treating an inflammatory or immunological disease or disorder or for treating arthritis comprising administering an effective amount of the composition of claim 1 to a subject in need thereof.